Loading...
Benefits versus risks of latest therapies in multiple sclerosis: a perspective review
Disease-modifying treatments for multiple sclerosis (MS) have now been available for almost 20 years. Interferon β (IFN-β) products and glatiramer acetate (GA) were the first available options and are now considered first-line agents for the treatment of MS. These medications have several years of f...
Na minha lista:
| Main Authors: | , |
|---|---|
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
SAGE Publications
2012
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4110840/ https://ncbi.nlm.nih.gov/pubmed/25083243 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/2042098612462599 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|